Core Viewpoint - The sudden discontinuation of the Alzheimer's drug, 甘露特钠胶囊 (brand name "九期一"), by Green Valley Pharmaceutical has led to a crisis for patients relying on this medication, with reports of counterfeit drugs flooding the market as a result of the supply shortage [1][2][4]. Group 1: Drug Supply Crisis - The discontinuation of 甘露特钠胶囊 began in early May 2025 and peaked in June, leaving many families of Alzheimer's patients in desperate search for alternatives [1][2]. - Green Valley Pharmaceutical stated that the production halt was due to the expiration of the drug's registration certificate, which is currently awaiting review [4]. Group 2: Counterfeit Drug Market - The shortage of the legitimate drug has led to a surge in counterfeit products being sold online, with misleading names such as "同仁堂甘露特钠胶囊" and "甘露药食同源浓缩丸" appearing on e-commerce platforms [6][11]. - Prices for the legitimate drug have skyrocketed, with reports of it being sold for as much as 5000 yuan per box, compared to the original monthly cost of approximately 296 yuan after insurance [4][2]. Group 3: Brand Misuse and Legal Issues - The issue of brand misuse is not new for 同仁堂, which previously reported 65 instances of its name being used fraudulently in March 2025 [11]. - The sale of counterfeit drugs has been identified as a criminal offense, with a notable case in May 2024 involving a live-streaming fraud scheme that targeted older adults, resulting in a financial loss of 30.89 million yuan [13].